Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study

Zwerina, Jochen; Bach, Christian; Martorana, Davide; Jatzwauk, Maria; Hegasy, Guido; Moosig, Frank; Bremer, Jan Phillip; Wieczorek, Stefan; Moschen, Alexander R.; Tilg, Herbert; Neumann, Thomas; Spriewald, Bernd M.; Schett, Georg; Vaglio, Augusto

doi:10.1093/rheumatology/keq445

Cited by 78 publications

(51 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent study comparing patients with EGPA ANCA-negative and HES FIP1L1-PDGFRA-negative, none of the analyzed serum biomarkers (sIL2R, IL-5, IL-6, IL-8, IL-10, CCL17, eotaxin-1) could differentiate between the two groups of patients [80]. As previously mentioned, eotaxin-3 could differentiate active EGPA from various forms of HES, as well as from other allergic or immune diseases associated with eosinophilia [11,82].…”

Section: Hypereosinophilic Syndrome (Hes)mentioning

confidence: 87%

“…It is important to highlight that all HES patients had active disease at the time of blood collection. In a cutoff point of 80 pg/mL, the sensitivity and specificity of eotaxin-3 for diagnosing active EGPA was 87.5% and 98.6%, respectively [11]. Although this biomarker needs diagnostic validation, it is likely to come into use in daily clinical practice.…”

Section: Blood Cells and Biomarkersmentioning

confidence: 99%

“…Since anti-neutrophil cytoplasmic antibodies (ANCA) have been found in a proportion of patients, EGPA has subsequently been included in the spectrum of ANCA-associated vasculitis (AAV), along with GPA and microscopic polyangiitis (MPA) [4]. Several studies have elucidated the role of immune mechanisms, identifying genetic associations with HLA-DRB4 while recognizing new diagnostic and follow-up biomarkers (e.g., eotaxin-3) [5][6][7][8][9][10][11]. Finally, the treatment approach has improved through the use of immunosuppressive drugs and biological treatments.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Churg-Strauss Syndrome or Eosinophilic Granulomatosis with Polyangiitis

et al. 2015

View full text Add to dashboard Cite

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss, EGPA) is a systemic small-to-medium-sized vasculitis associated with asthma and eosinophilia. Histologically EGPA presents tissue eosinophilia, necrotizing vasculitis, and granulomatous inflammation with eosinophil tissue infiltration. EGPA commonly involves the upper airway and lung parenchyma, peripheral neuropathy, cardiac disorders, and skin lesions. The anti-neutrophil cytoplasmic antibodies (ANCA) are positive in 40% of cases, especially in those patients with clinical signs of vasculitis. The pathogenesis of EGPA is multifactorial. The disease can be triggered by exposure to a variety of allergens and drugs, but a genetic background has also been described, particularly an association with HLA-DRB4. Th2 response is of special importance in the upregulation of different interleukins such as IL-4, IL-13, and IL-5. Th1 and Th17 responses are also of significance. Activated eosinophils have a prolonged survival and probably cause tissue damage by releasing eosinophil granule proteins, while their tissue recruitment can be regulated by chemokines such as eotaxin-3 and CCL17. Humoral immunity is also OPEN ACCESSSinusitis 2016, 1 25 abnormally regulated, as demonstrated by excessive responses of IgG4 and IgE. EGPA has a good respond to glucocorticoids, although the combination of glucocorticoids and immunosuppressants (e.g., cyclophosphamide, azathioprine) is needed in most of cases. Newer treatment options include anti-IL-5 antibodies (mepolizumab), whose efficacy has been described in clinical trials, and anti-CD-20, a B cell-depleting agent (rituximab), reported in several case series.

show abstract

Section: Hypereosinophilic Syndrome (Hes)mentioning

confidence: 87%

Section: Blood Cells and Biomarkersmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Churg-Strauss Syndrome or Eosinophilic Granulomatosis with Polyangiitis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The Journal on March 22, 2019 -Published by www.jrheum.org Downloaded from Letter of 80 pg/ml, its sensitivity and specificity reached 87.5% and 98.6%, respectively 9 . In a multicenter study, in 25 patients with established EGPA, serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4:IgG ratio did not differentiate active disease and remission 8 .…”

Section: Clinical Characteristicsmentioning

confidence: 93%

“…In the previous studies, it was suggested that serum eotaxin-3 levels could discriminate EGPA from a broad spectrum of rheumatic diseases 6,9 . Eotaxin-3 was also a reliable biomarker for active EGPA.…”

Section: To the Editormentioning

confidence: 99%